BOTHELL, Wash., Nov. 15, 2023 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented new preclinical data supporting the potential therapeutic benefit of fosgonimeton for the treatment of Alzheimer’s disease (AD) and other…Read More
Athira Pharma Inc Athira Pharma Presents Preclinical Data Highlighting Fosgonimetons Neuroprotective Effects Against AmyloidInduced Pathological Alterations and Neuroinflammation in Models of Alzheimers Disease
